IGC Pharma: A High-Stakes Bet on Alzheimer’s Innovation

The recent trading activity for India Globalization Capital (IGC Pharma) presents a classic case of biotech volatility. Despite announcing significant clinical progress for its Alzheimer’s treatment, the company’s shares closed at €0.33 on Friday, continuing a downward trend that contrasts sharply with a recent surge. This price action leaves investors questioning whether the stock’s movements are driven by speculation or if the company is on the cusp of a major breakthrough.

Clinical Progress Amid Market Pessimism

The fundamental story for IGC Pharma appears compelling, even as its share price weakens. The company’s lead drug candidate, IGC-AD1, is being developed to address agitation in Alzheimer’s patients—a substantial market with significant unmet needs. The clinical program is advancing seriously, underscored by the expansion... Read more...